Revalesio - News

+ RECENT NEWS

+ ARCHIVE

Revalesio to Present New Parkinson’s Data at the American Academy of Neurology “Future of Neuroscience” Conference

Date: April 25, 2012

Researchers from Rush University and Revalesio Corporation will be presenting two studies related to developing novel treatments for neuro-inflammatory disease at the Annual Meeting of the American Academy of Neurology (AAN), April 21-28, 2012 in New Orleans, Louisiana.

Rush University Study Demonstrates Neuro-protective and Anti-inflammatory Activity of RNS60

Date: March 6, 2012

Researchers from Rush University and Revalesio Corporation will be presenting two studies related to developing novel treatments for neuro-inflammatory disease at The American Society for Neurochemistry Annual Conference (ASN) March 3-7, 2012 in Baltimore, Maryland.

Revalesio’s RNS60 Reduces Cardiac Damage in Pig Study of Heart Attacks

Date: November 14, 2011

Revalesio Corporation is presenting pre-clinical data at the American Heart Association (AHA) Scientific Sessions demonstrating the use of RNS60 may have beneficial effects on cardiac damage associated with heart attacks. The AHA Scientific Sessions are the preeminent cardiovascular meeting for researchers and clinicians and is being held November 12-16 in Orlando, Florida.

Revalesio Successfully Completes Phase I Intravenous Safety Study of RNS60

Date: November 14, 2011

Revalesio Corporation has successfully completed a first-in-man clinical trial of RNS60 using intravenous (I.V.) dosing. The study, conducted in conjunction with Quintiles in Overland Park, Kansas, met all safety endpoints and supports the unparalleled safety profile of RNS60 as a novel anti-inflammatory therapeutic.

Revalesio’s RNS60 demonstrates promise in first human asthma trial

Date: October 31, 2011

Tacoma, WA – Revalesio Corporation will present clinical efficacy and safety data for RNS60 at the annual ACAAI meeting in Boston, November 3-8. ACAAI (American College of Allergy, Asthma and Immunology) is a professional association with more than 5,000 members devoted to the specialty of allergy and immunology.

Katze lab signs contract with Revalesio to study novel approaches to viral diseases

Date: September 14, 2011

Revalesio, a pioneering biotechnology company based in Tacoma, recently signed an 18-month contract with the Katze lab at the University of Washington to bring hope to sufferers of influenza, HIV and hepatitis C.

Xconomy Editorial: Hitting the Target, Missing the Mark: How Targeted Therapies Have Left Patients Wanting

Date: April 14, 2011

Read article by Dr. Richard Watson on Xconomy.com

Revalesio Presents Multiple Sclerosis and Alzheimer’s Disease Research at National Neurology Conference

Date: April 4, 2011

Revalesio Corporation, a pioneering biotechnology company, and Rush University will present research on the use of RNS60 in Multiple Sclerosis and Alzheimer’s disease at the American Academy of Neurology (AAN) meeting April 9-16 in Honolulu, Hawaii.

Revalesio to present research on the anti-inflammatory effects of RNS60 in Asthma

Date: March 16, 2011

Tacoma, WA – Revalesio Corporation announced today that research related to the use of RNS60, its novel anti-inflammatory, will be featured in two poster presentations at the Annual Meeting of the American Academy of Allergy Asthma and Immunology (AAAAI) in San Francisco on March 18-22.

Alzheimer’s and Parkinson’s disease research presented by Revalesio at national scientific conference

Date: March 14, 2011

TACOMA, Wash. – Revalesio Corporation and Rush University will present research on the use of RNS60 at the American Society of Neurochemistry (ASN) meeting in St. Louis.

Revalesio partners with leading firm

Predictive Biomarker Sciences will assess potential cancer treatment

Date: October 20, 2010

TACOMA, Wash. – Revalesio Corporation announced today that it has contracted with Predictive Biomarker Sciences (PBS-Bio) to conduct studies related to the use of Revalesio’s novel anti-inflammatory therapeutic in treating cancer.

PBS-Bio works with 3 new firms to accelerate cancer drug development

Predictive Biomarker Sciences technology shows how drugs function along cellular pathways

MESA, Ariz. – Oct. 20, 2010 – In an industry that faces increasing challenges in delivering new drugs to patients, Predictive Biomarker Sciences (PBS-Bio) today announced three new contracts aimed at bringing new medicines to the marketplace.

Revalesio website opens window to inflammatory disease research

Date: September 10, 2010

Revalesio Corporation, a private biotechnology company, today announced the launch of its new website, www.revalesio.com.

Revalesio clinical trials to continue following positive initial results for asthma treatment

Date: August 1, 2010

Revalesio Corporation today announced positive results from the first section of its phase I clinical trial of RNS60, a charge-stabilized nanostructure therapy for the treatment of asthma. Patients experienced no toxicity or adverse events.

Revalesio announces initiation of Asthma Phase I/IIa trial

Date: May 19, 2010

Revalesio Corporation, a private biotechnology company, today announced the initiation of a Phase I/IIa trial of RNS60, the first product in a new class of anti-inflammatory drugs, to determine the safety and tolerability of RNS60 in healthy volunteers and mild asthmatics as measured by spirometry.

Revalesio announces Investigational New Drug approval for novel treatment of asthma

Date: May 7, 2010

Tacoma, WA– Revalesio Corporation announced today that the FDA approved its plans to study RNS60, a novel anti-inflammatory product. Revalesio will conduct the Phase I/IIa clinical trial in partnership with Stanford University and West Coast Clinical Trials.